Super Bowl, Hims
Hims & Hers hit the bulls-eye with its Super Bowl ad—it sparked a lot of attention from consumers to check out its brand and ...
Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...
Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...
Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
The goal is to either have the put expire worthless and keep the premium, or to be assigned and acquire the stock below the ...
Hims & Hers, a San Francisco-headquartered telehealth company, ran its controversial Super Bowl commercial despite multiple ...
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results